Cargando…

Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers

INTRODUCTION: This study aimed to determine the efficacy of combining plasma phosphorylated tau (p‐tau)181, amyloid beta (Aβ)42/Aβ40, neurofilament light (NfL), and apolipoprotein E (APOE) genotypes for detecting positive amyloid positron emission tomography (PET), which is little known in the Asian...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Hyuk Sung, Lee, Eun‐Hye, Kim, Hyung‐Ji, Park, So‐Hee, Park, Hyun‐Hee, Jeong, Jee Hyang, Koh, Seong‐Ho, Choi, Seong Hye, Lee, Jae‐Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654468/ https://www.ncbi.nlm.nih.gov/pubmed/38026758 http://dx.doi.org/10.1002/dad2.12502

Ejemplares similares

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Clinical Significance of Physical Frailty in Subjects With Subjective Cognitive Decline: A Prospective Study With Amyloid PET Data
por: Lim, Eun Ye, et al.
Publicado: (2023)

Predictive Scale for Amyloid PET Positivity Based on Clinical and MRI Variables in Patients with Amnestic Mild Cognitive Impairment
por: Chun, Min Young, et al.
Publicado: (2022)

The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease
por: Park, So-Hee, et al.
Publicado: (2021)

Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition
por: Rauchmann, Boris Stephan, et al.
Publicado: (2021)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
por: Jeon, Seun, et al.
Publicado: (2019)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Clinical significance of focal ß-amyloid deposition measured by (18)F-flutemetamol PET
por: Kim, Si Eun, et al.
Publicado: (2020)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity
por: Pyun, Jung-Min, et al.
Publicado: (2021)

Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
por: Yu, Lei, et al.
Publicado: (2023)

Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment
por: Chen, Jingshan, et al.
Publicado: (2023)

Plasma phosphorylated tau181 predicts cognitive and functional decline
por: Tropea, Thomas F., et al.
Publicado: (2022)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Serum neurofilament light chain level as a predictor of cognitive stage transition
por: Lee, Eun-Hye, et al.
Publicado: (2022)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
por: Batzu, Lucia, et al.
Publicado: (2022)

Association between sleep parameters and longitudinal shortening of telomere length
por: Jin, Jeong-Hwa, et al.
Publicado: (2022)

Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans: CSF AD biomarkers measured by Lumipulse in Koreans
por: Moon, Sohee, et al.
Publicado: (2021)

Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders
por: Tzartos, John S., et al.
Publicado: (2022)

Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults
por: Han, Myung-Hoon, et al.
Publicado: (2023)

Neural Stem Cell Death Mechanisms Induced by Amyloid Beta
por: Lee, Jongmin, et al.
Publicado: (2017)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Comparing Neurofilament Light Chain Levels in Serum and Plasma
por: Kwon, Hyuk Sung, et al.
Publicado: (2023)

A Positive Association between the Atherogenic Index of Plasma and White Matter Hyperintensity
por: Kwon, Hyun-Suk, et al.
Publicado: (2022)

Centiloid method evaluation for amyloid PET of subcortical vascular dementia
por: Yun, Hyuk Jin, et al.
Publicado: (2017)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Effects of the multidomain intervention with nutritional supplements on cognition and gut microbiome in early symptomatic Alzheimer’s disease: a randomized controlled trial
por: Lee, Eun Hye, et al.
Publicado: (2023)

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
por: Brickman, Adam M., et al.
Publicado: (2021)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result
por: Westwood, Sarah, et al.
Publicado: (2018)

Association of Subcortical Structural Shapes With Tau, Amyloid, and Cortical Atrophy in Early-Onset and Late-Onset Alzheimer’s Disease
por: Lee, Eun-Chong, et al.
Publicado: (2020)

Spontaneously Reported Hepatic Adverse Drug Events in Korea: Multicenter Study
por: Kwon, Hee, et al.
Publicado: (2012)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
por: Tsantzali, Ioanna, et al.
Publicado: (2022)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer’s disease as an indicator of tau phosphorylation
por: Shim, Kyu Hwan, et al.
Publicado: (2020)

Relationship between telomere shortening and age in Korean individuals with mild cognitive impairment and Alzheimer’s disease compared to that in healthy controls
por: Lee, Eun-Hye, et al.
Publicado: (2020)

Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta‐analyses
por: Alhajraf, Falah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qogl9b4nu97adhunt0bb5aoprp